HEPATIQ REPORT
The HEPATIQ physician report provides six quantitative indices of liver disease that may be used for diagnosis, staging, interventions, and monitoring disease progression. It includes color-coded serial and differential graphs and an interpretation of the quantitative indices. A sample report is shown below for illustration.
.png)
- The HEPATIQ report provides the following quantitative indices of liver disease:
- PHM - Quantitative Liver Function (normal ≥100). Patients with PHM < 95 have cirrhosis and an almost 15-fold increase in the risk of clinical outcomes such as ascites, variceal bleeding, hepatic encephalopathy, and death.
- fLV – Liver Volume (7 ≤ normal < 12). This index together with PHM can be used to differentially diagnose fatty liver, steatohepatitis and cirrhosis.
- fSV - Spleen Volume (>0 normal < 2.5). This index together with PHM can be used to differentially diagnose portal hypertension, infiltrative spleen disease and cirrhosis.
- HAI - Activity Index (normal > -0.1). This index captures the effect of alcoholic activity and may be used to diagnose alcoholic hepatitis and distinguish ASH and NASH.
- eFS - Fibrosis Score (normal = 0, range 0 to 6). This categorical index of liver fibrosis correlates with the Ishak fibrosis score.
- eEV - Esophageal Varices (normal =0, range 0 to 3). This categorical index estimates presence and size of esophageal varices and the risk of bleeding.
The HEPATIQ indices have myriad uses:
- Decompensation: For patients with severe fibrosis or cirrhosis, PHM and fSV indicate likelihood of liver decompensation (outcomes such as ascites, varices, encephalopathy, etc.).
- Portal Hypertension: fSV provides a simple non-invasive indication of portal hypertension. May be useful for assessing a transjugular intrahepatic portosystemic shunt (TIPS).
- Hemodynamics: PHM and fLV indicate intrahepatic hemodynamic conditions allowing differentiation of acute and chronic liver disease.
- Steatohepatitis: HAI and fLV allow differentiation of alcoholic steatohepatitis (ASH) and nonalcoholic steatohepatitis (NASH).
- Interventions: For HCC patients being considered for radioembolization or chemotherapy, PHM indicates likelihood of post-intervention liver failure.
- Transplantation: For patients with severe liver disease but MELD score not high enough for transplant priority, low PHM may be used to justify a MELD exception.
- Therapy: PHM provides an objective assessment of the efficacy of pharmacological, radiological or surgical therapies for the underlying causes of liver disease.